Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer
Investors had been “holding out hope” that there remained a regulatory path forward for RP1, but results of Replimune’s Type A meeting with the FDA do not appear to support this, according to BMO Capital Markets.
Replimune Crashes as Uncertainty Clouds Regulatory Path for Tumor Destroyer Read More »
